Compound for Attenuation of Diazepam Induced Withdrawal Syndrome

The present disclosure relates generally to the field of pharmaceuticals. Specifically, the present disclosure is directed to a compound, diminazene aceturate, for the treatment, amelioration, attenuation or prevention of diazepam dependence induced withdrawal syndrome. Diminazene aceturate is an ASIC1a modulator and the withdrawal symptoms are precipitated using flumazenil.


Gurjeet Thakur, Amarjot Kaur Grewal

Patent File Number - 202011026265        Patent File Date - 22/06/2020